Christophe Beauduin

Special Counsel
Full contact info

Experience

Scorpion Therapeutics Announces Collaboration and License Agreement With Pierre Fabre to Co-Develop and Commercialize STX-721 and STX-241

April 4, 2023

Boston – April 4, 2023 Cooley advised Scorpion Therapeutics on its exclusive license agreement with Pierre Fabre to co-develop and commercialize STX-721 and STX-241. Lawyers Christophe Beauduin, Carly Robinson, Michael Klein, Evan Lazerowitz and Aaron Pomeroy led the Cooley team.

The exclusive collaboration and license agreement granted Pierre Fabre a royalty-bearing license to develop and commercialize STX-721 and STX-241, two next-generation mutant epidermal growth factor receptor (EGFR) inhibitors for patients with EGFR-mutant non-small cell lung cancer. Scorpion will lead clinical development of STX-721, and Pierre Fabre will lead clinical development of STX-241. Scorpion will retain commercialization rights to STX-721 and STX-241 in the US, Canada and Japan, while Pierre Fabre will be responsible for commercialization activities in all other territories – with a focus on Europe and China.

Under the terms of the agreement, Scorpion will receive a combined $65 million from an upfront payment and achievement of near-term milestones – and will be eligible to receive up to a total of $553 million in potential milestone payments. In addition, Pierre Fabre will pay Scorpion tiered percentage royalties on a licensed product-by-licensed product basis, ranging from mid-single to mid-teens based on annual net sales of each licensed product in territories excluding the US, Canada and Japan. Scorpion will pay Pierre Fabre tiered percentage royalties based on a licensed product-by-licensed product basis, ranging from low-single to low-double digits on annual net sales of each licensed product in the US. The companies will share global development expenses based on a pre-specified cost-sharing arrangement.

Read more

Related contacts

Christophe Beauduin
Special Counsel, New York
Carly Robinson
Associate, Reston
Michael Klein
Partner, New York
Evan Lazerowitz
Associate, New York
Aaron Pomeroy
Partner, Colorado

CinCor Pharma to Sell to AstraZeneca for Approximately $1.8 Billion

January 10, 2023

Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.

Read more

Related contacts

Rowook Park
Partner, San Diego
Rama Padmanabhan
Partner, San Diego
Div Gupta
Partner, New York
Sarah Sellers
Partner, New York
Christophe Beauduin
Special Counsel, New York
Benjamin “Izzy” Lubarsky
Associate, New York
Alessandra Murata
Partner, Palo Alto
Ajay Athavale
Associate, San Francisco
Megan Drill
Associate, San Diego
Melissa Meza
Associate, San Diego
Trey Reilly
Associate, New York
Amy Hallman Rice
Special Counsel, San Diego
Matthew D. Silverman
Special Counsel, San Diego
Howard Morse
Partner, Washington DC
Sharon Connaughton
Special Counsel, Washington DC
Rubin Waranch
Associate, Washington DC
Natasha Leskovsek
Of Counsel, Washington DC
Phil Mitchell
Partner, New York
Charity Williams
Partner, San Diego
MaryBeth Shreiner
Associate, Reston
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Patrick Sharma
Associate, Los Angeles Santa Monica
Karen Tsai
Special Counsel, Washington DC
Heidi A. Erlacher
Partner, Boston
Kristopher Kleiner
Special Counsel, Colorado
Ryan Sansom
Partner, Boston
Stephanie Gentile
Partner, New York
Aric Wu
Partner, New York
Christopher Kimball
Partner, Washington DC
Nyron J. Persaud
Partner, New York
Helenanne Connolly
Partner, Reston
Stella Sarma
Special Counsel, Brussels
Stella Sarma
Special Counsel, Brussels
Stacey A. Bradford
Special Counsel, Washington DC
Christine Graham
Special Counsel, London
Dillon Martinson
Special Counsel, Washington DC
Lindsey O'Crump
Associate, Washington DC
Vivian Tsai
Associate, Los Angeles Santa Monica
Arman Sagart
Associate, San Diego
Daniel Gillon
Associate, San Diego
Barry Kuang
Associate, Boston
Rajdeep Roger Bains
Associate, San Diego
Alexander Fullman
Associate, New York
Amanda Gonzalez Burton
Associate, New York
Grace Hunter
Associate, Washington DC
Kindall G. Jackson
Associate, Washington DC
Dr. Xixi Sun
Associate, Boston
Sarah Curry
Associate, New York
Carly Mitchell
Associate, Washington DC
Jennifer Shanley
Special Counsel, New York
Wyatt Kernell
Associate, New York
Allison Kutner
Associate, New York

Related Practices & Industries

Scorpion Therapeutics Enters Collaboration Agreement with AstraZeneca

January 14, 2022

Cooley advised Scorpion Therapeutics in its collaboration agreement with AstraZeneca to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.

Under the terms of the collaboration agreement, Scorpion will receive an upfront cash payment of $75 million and is eligible to receive additional success-based payments in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits. In the event Scorpion opts into co-developing and co-promoting a nominated program, Scorpion will participate in the operating costs and be entitled to a proportionate share of the economics in the US, subject to certain adjustments.

 

Related contacts

Christophe Beauduin
Special Counsel, New York
Carly Robinson
Associate, Reston

Related Practices & Industries

Nykode Therapeutics Enters Collaboration Agreement with Regeneron

November 24, 2021

Cooley advised Nykode Therapeutics in its license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases. 

Under the terms of the agreement, Nykode Therapeutics will receive a $30 million upfront payment and a $20 million equity investment at a premium of 20% on a 30-day volume weighted average price of the Nykode Therapeutics share for the last 30 trading days before the effective date of the agreement. Additionally, Nykode Therapeutics will potentially be eligible to receive more than $875 million in milestone payments, plus high single-digit to low double-digit tiered royalties on sales of commercialized products arising from the collaboration, bringing the total potential value of the agreement to more than $925 million, plus royalties.

Lawyers Ken Krisko, Christophe Beauduin, John Forrest, Marya Postner and Hajra Nashin led the Cooley team advising Nykode. 

 

Related contacts

Kay Chandler
Partner, San Diego
Christophe Beauduin
Special Counsel, New York
John Forrest
Associate, Boston
Marya Postner
Partner, Palo Alto
Hajra Nashin
Associate, San Diego

Related Practices & Industries